Dr Roberto Salgado
Clinical (Senior Lecturer)
The Sir Peter MacCallum Department of Oncology
547 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Clarifying validation terminologies in healthcare
DOI: 10.1038/s41746-026-02471-22026
Journal article
Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
DOI: 10.1038/s41467-026-72956-x2026
Journal article
World Health Organization classification of tumours of the breast 6th edition 2026
DOI: 10.1111/his.701492026
Journal article
Stage-related transcriptional changes in HR-positive/HER2-negative breast cancer.
DOI: 10.1038/s41523-026-00973-62026
Journal article
Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study
DOI: 10.1016/j.esmoop.2026.1077312025
Research grants (international)
Validation and Comparison of Computational Pathology-Measured Immune-Biomarkers Using AI-and AI-foundation Models With Patient Level Outcomes in Multiple Randomized Breast Cancer Trials.
2014
Journal article
Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
DOI: 10.1186/s13059-014-0470-7
RECENT SCHOLARLY WORKS
2026
Journal article
AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.
DOI: 10.1038/s41523-026-00999-w2026
Journal article
Artificial Intelligence (AI)-Assisted Human Epidermal Growth Factor Receptor 2 (HER2) Scoring in Breast Cancer: Diagnostic Agreement and Understanding Discordance.
DOI: 10.1016/j.labinv.2026.1061502026
Journal article
Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
DOI: 10.1200/jco.2026.44.16_suppl.5542026
Journal article
Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity
DOI: 10.1158/1078-0432.CCR-25-40352026
Journal article
AI-based assessment of tumor-infiltrating lymphocytes (TILs) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy versus chemo-immunotherapy.
DOI: 10.1200/JCO.2026.44.16_suppl.e12583